Delivery Order SPE2DB24D3013-SPE2DB25FFQDE
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $37,878.75 to AmerisourceBergen Drug Corp for the supply of IMBRUVICA 420 mg tablets (28-count units) on August 14, 2025, with an ultimate completion date of September 5, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order valued at $22,727.25 to AmerisourceBergen Drug Corp for the supply of Imbruvica 420 mg tablets (28-count package), with an ultimate completion date of August 8, 2025. This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement and is being performed from the awardee's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Imbruvica 420 mg tablets (28-count) with a ceiling value of $76,839.82. This firm fixed-price delivery order, with an ultimate completion date of September 9, 2025, represents a competitive award with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Imbruvica 420 mg tablets (28-count units) valued at $53,030.25 with a firm fixed price structure. The order is scheduled for completion by September 9, 2025, and will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a non-set-aside, competitively awarded contract and is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $16,233.74 to AmerisourceBergen Drug Corp for the supply of Imbruvica 140 mg capsules (90-count units) on September 3, 2025, with an ultimate completion date of September 24, 2025. This firm fixed-price, competitively awarded delivery order was placed without set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract executed under...
- The Defense Logistics Agency awarded a $7,575.75 delivery order to AmerisourceBergen Drug Corp on August 22, 2025, for the supply of Imbruvica 140 mg tablets (28-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation, scheduled for completion by September 15, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $15,151.52 to AmerisourceBergen Drug Corp for the supply of IMBRUVICA 420 mg tablets (28-count units) under a firm fixed price contract. This non-competitive set-aside delivery order is scheduled for completion by September 2, 2025, with performance at the contractor's facility in Conshohocken, Pennsylvania. The award represents a continuation of pharmaceutical supply services through AmerisourceBergen's extensive federal...
- The Defense Logistics Agency awarded a $7,575.75 delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Imbruvica 420 mg tablets (28-count units). This is a firm fixed price, non-set-aside contract with an ultimate completion date of September 9, 2025. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,575.75 to AmerisourceBergen Drug Corp for the supply of IMBRUVICA 420 mg tablets (28-count units) with delivery to Conshohocken, Pennsylvania. This contract, awarded on August 4, 2025, utilizes a firm fixed-price structure with an ultimate completion date of August 25, 2025. The award was made without a set-aside designation, indicating it was competitively awarded among qualified vendors. This delivery order represents a...
- The Defense Logistics Agency awarded a $7,575.75 firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Imbruvica 420 mg tablets (28-count units). This non-set-aside contract is scheduled for completion by September 10, 2025, with performance taking place at the vendor's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical...
- SPE2DB24D3013Indefinite Delivery Contract
- SPE2DB24D3013-SPE2DB25FFQDEDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $15,151.52 to AmerisourceBergen Drug Corp for the supply of Imbruvica 280 mg tablets (28-count units) on September 4, 2025, with completion expected by September 25, 2025. This firm fixed-price delivery order was competitively awarded without set-aside provisions and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract action under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion comprehensive pharmaceutical supply vehicle running through December 2026. AmerisourceBergen Drug Corp serves as a critical pharmaceutical distributor for federal medical procurement, supplying military and veteran healthcare systems with an extensive portfolio of brand-name and generic medications, vaccines, and specialized medical supplies. This delivery order for Imbruvica, a specialty pharmaceutical used in hematologic malignancy treatment, demonstrates the company's role in supporting the Defense Health Agency and other government healthcare customers. The contract reflects DLA's ongoing pharmaceutical supply chain operations, which will transition to the Pharmaceutical Prime Vendor Global Program Generation V structure, anticipated to include multiple regional awards among competing contractors.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $15.2k | 9/4/25 |